Skip to main content
. 2020 Dec 8;12(12):1191. doi: 10.3390/pharmaceutics12121191

Figure 2.

Figure 2

Example comparisons of model-predicted and observed CYP1A2 DDI outcomes: (a) Predicted and observed caffeine concentrations, with and without coadministration of fluvoxamine; (b) predicted and observed mean (±standard deviation) concentrations of tizanidine after 4 mg dose given with or without fluvoxamine using the optimized Ki value; gray area encompasses the standard deviation interval of the predicted profiles; (c) predicted and observed mean (±standard deviation) mexiletine concentrations with (red) and without (blue) fluvoxamine. Additional comparisons of model-predicted vs. observed DDI outcomes can be found in Supplementary Material S3. CYP, cytochrome P450.